Clinical Trial Update: Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial assessing denileukin diftitox in patients with Stage IIIC and Stage IV melanoma has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Stage Iiic Melanoma

Drugs mentioned

• Denileukin diftitox (denileukin diftitox)

Snippet

Sponsor: Eisai Inc. | Conditions: Stage IIIC Melanoma, Stage IV Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2022-04-13